<?xml version="1.0" encoding="UTF-8"?>
<Bundle xmlns="http://hl7.org/fhir">
    <id value="bundle-epi-talzenna"/>
    <url
        value="https://github.com/HL7/emedicinal-product-info/blob/master/input/resources/BundlePlTalzenna"/>
    <identifier>
        <system value="https://www.gravitatehealth.eu/sid/doc"/>
        <value value="EMEA/H/C/004674"/>
    </identifier>
    <type value="document"/>
    <timestamp value="2019-06-20T00:00:00Z"/>
    <entry>
        <fullUrl value="urn:uuid:e63f72b2-993f-48b1-b7cb-539b1ed71571"/>
        <resource>
            <Composition>
                <status value="final"/>
                <type>
                    <coding>
                        <system value="https://spor.ema.europa.eu/rmswi"/>
                        <code value="100000155538"/>
                    </coding>
                    <text value="Package Leaflet"/>
                </type>
                <extension url="http://ema.europa.eu/fhir/extension/domain">
                    <valueCoding>
                        <system value="https://spor.ema.europa.eu/v1/100000000004"/>
                        <code value="100000000012"/>
                        <display value="H"/>
                    </valueCoding>
                </extension>
                <date value="2019-06-20T00:00:00Z"/>
                <author>
                    <identifier>
                        <system value="http://spor.ema.europa.eu/v1/locations"/>
                        <value value="LOC-100016576"/>
                    </identifier>
                </author>
                <title
                    value="Package leaflet: Talzenna (talazoparib) 0.25 mg hard capsules, 1 mg hard capsultes"/>
                <section>
                    <title value="Package Leaflet"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029894"/>
                            <display value="Package Leaflet"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>
                                <b>Talzenna 0.25 mg hard capsules</b>
                            </p>
                            <p>
                                <b>Talzenna 1 mg hard capsules</b>
                            </p>
                            <p>talazoparib</p>
                            <p>&#9660; This medicine is subject to additional monitoring. This will
                                allow quick identification of new safety information. You can help
                                by reporting any side effects you may get. See the end of section 4
                                for how to report side effects.</p>
                            <p>
                                <b>Read all of this leaflet carefully before you start taking this
                                    medicine because it contains important information for you.</b>
                            </p>
                            <ul>
                                <li>Keep this leaflet. You may need to read it again.</li>
                                <li>If you have any further questions, ask your doctor or
                                    pharmacist.</li>
                                <li>This medicine has been prescribed for you only. Do not pass it
                                    on to others. It may harm them, even if their signs of illness
                                    are the same as yours.</li>
                                <li>If you get any side effects, talk to your doctor or pharmacist.
                                    This includes any possible side effects not listed in this
                                    leaflet. See section 4.</li>
                            </ul>
                            <p>
                                <b>What is in this leaflet</b>
                            </p>
                            <ul>
                                <li>What Talzenna is and what it is used for</li>
                                <li>What you need to know before you take Talzenna</li>
                                <li>How to take Talzenna</li>
                                <li>Possible side effects</li>
                                <li>How to store Talzenna</li>
                                <li>Contents of the pack and other information</li>
                            </ul>
                        </div>
                    </text>
                </section>
                <section>
                    <title value="1. What Talzenna is and what it is used for"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029895"/>
                            <display value="1. What X is and what it is used for"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>
                                <b>What Talzenna is and how it works </b>
                            </p>
                            <p>Talzenna contains the active substance talazoparib. It is a type of
                                anticancer medicine known as a ‘PARP (poly-ADP ribose polymerase)
                                inhibitor’. </p>
                            <p>Patients with changes (mutations) in genes called BRCA are at risk of
                                developing some forms of cancer. Talzenna works by blocking PARP,
                                which is an enzyme that repairs damaged DNA in certain cancer cells.
                                As a result, the cancer cells can no longer repair themselves and
                                they die. </p>

                            <p>
                                <b>What Talzenna is used for </b>
                            </p>
                            <p>Talzenna is used to treat adults with breast cancer of a type known
                                as HER2-negative breast cancer who have an abnormal inherited BRCA
                                gene. </p>
                            <p>Talzenna is used when the cancer has spread beyond the original
                                tumour or to other parts of the body. Your healthcare provider will
                                perform a test to make sure that Talzenna is right for you. </p>
                            <p>If you have any questions about how Talzenna works or why this
                                medicine has been prescribed for you, ask your doctor. </p>
                        </div>
                    </text>
                </section>
                <section>
                    <title value="2. What you need to know before you take Talzenna"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029896"/>
                            <display value="2. What you need to know before you {take{ {use} X"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml"/>
                    </text>
                    <section>
                        <title value="Do not take Talzenna"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029897"/>
                                <display value="Do not {take}; {use} X"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <ul>
                                    <li>
                                        <p>If you are allergic to talazoparib or any of the other
                                            ingredients of this medicine (listed in section 6). </p>
                                    </li>
                                    <li>
                                        <p>If you are breast-feeding. </p>
                                    </li>
                                </ul>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Warnings and precautions"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029898"/>
                                <display value="Warnings and precautions"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Talk to your doctor, pharmacist or nurse before taking Talzenna
                                    and during your treatment if you experience signs or symptoms
                                    described in this section. </p>
                                <p>
                                    <u>Low blood cell counts</u>
                                </p>
                                <p>Talzenna lowers your blood cell counts, such as your red blood
                                    cell count (anaemia), white blood cell count (neutropenia), or
                                    blood platelet count (thrombocytopenia). Signs and symptoms you
                                    need to look out for include: </p>
                                <ul>
                                    <li>
                                        <p><b>Anaemia: </b>Being short of breath, feeling very
                                            tired, pale skin, or fast heartbeat – these may be </p>
                                        <p>signs of a low red blood cell count </p>
                                    </li>
                                    <li>
                                        <p><b>Neutropenia: </b>Infection, developing chills or
                                            shivering, or fever – these may be signs of a low </p>
                                        <p>white blood cell count </p>
                                    </li>
                                    <li>
                                        <p><b>Thrombocytopenia: </b>Bruising or bleeding for longer
                                            than usual if you hurt yourself – these may be signs of
                                            a low blood platelet count</p>
                                    </li>
                                </ul>
                                <p>You will have regular blood tests during treatment with Talzenna
                                    to check your blood cells (white blood cells, red blood cells,
                                    and platelets). </p>
                                <p>
                                    <u>Serious problems with the bone marrow</u>
                                </p>
                                <p>Rarely, low blood cell counts may be a sign of more serious
                                    problems with the bone marrow such as myelodysplastic syndrome
                                    (MDS) or acute myeloid leukaemia (AML). Your doctor may want to
                                    test your bone marrow to check for these problems. </p>
                                <p>
                                    <u>Male and female contraception</u>
                                </p>
                                <p>Women who can become pregnant and men with partners who are or
                                    can become pregnant should use effective contraception.</p>
                                <p>Please see section “Male and female contraception” below. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Children and adolescents"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029899"/>
                                <display value="Children {and adolescents}"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Talzenna is not to be used in children or adolescents (under 18
                                    years of age). </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Other medicines and Talzenna"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029900"/>
                                <display value="Other medicines and X"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Tell your doctor, pharmacist or nurse if you are taking, have
                                    recently taken or might take any other medicines. This includes
                                    medicines obtained without a prescription and herbal medicines.
                                    This is because Talzenna can affect the way some other medicines
                                    work. Also some medicines can affect the way Talzenna works. </p>
                                <p>In particular, the following may increase the risk of side
                                    effects with Talzenna:</p>
                                <ul>
                                    <li>
                                        <p>Amiodarone, carvedilol, dronedarone, propafenone,
                                            quinidine, ranolazine and verapamil – </p>

                                        <p>generally used to treat heart problems. </p>
                                    </li>
                                    <li>
                                        <p>Clarithromycin and erythromycin antibiotics – used to
                                            treat bacterial infections. </p>
                                    </li>
                                    <li>
                                        <p>Itraconazole and ketoconazole – used to treat fungal
                                            infections. </p>
                                    </li>
                                    <li>
                                        <p>Cobicistat, darunavir, indinavir, lopinavir, ritonavir,
                                            saquinavir, telaprevir and tipranavir used to </p>
                                        <p>treat HIV infections/AIDS. </p>
                                    </li>
                                    <li>
                                        <p>Ciclosporin – used in organ transplantation to prevent
                                            rejection. </p>
                                    </li>
                                    <li>
                                        <p>Lapatinib – used to treat patients with certain types of
                                            breast cancer. </p>
                                    </li>
                                    <li>
                                        <p>Curcumin (e.g. found in turmeric root) in some medicines
                                            (see also section Talzenna with food and drink
                                            below).</p>
                                    </li>
                                </ul>
                                <p>The following medicines may reduce the effect of Talzenna: </p>
                                <ul>
                                    <li>
                                        <p>Carbamazepine and phenytoin – anti-epileptics used to
                                            treat seizures or fits. </p>
                                    </li>
                                    <li>
                                        <p>St. John’s wort (<i>Hypericum perforatum</i>) – a herbal
                                            remedy used to treat mild depression and </p>
                                        <p>anxiety. </p>
                                    </li>
                                </ul>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Talzenna with food and drink"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029901"/>
                                <display value="X with {food} {and} {,} {drink} {and} {alcohol}"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Do not use curcumin in food supplements while you are taking
                                    Talzenna as it may increase Talzenna’s side effects. Curcumin is
                                    found in turmeric root and you should not use large amounts of
                                    turmeric root, but using spices in food is not likely to cause a
                                    problem. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Pregnancy"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029902"/>
                                <display value="Pregnancy {and} {,} breast-feeding {and fertility}"
                                />
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Talzenna could harm an unborn baby. If you are pregnant or
                                    breast-feeding, think you may be pregnant or are planning to
                                    have a baby, ask your doctor or pharmacist for advice before
                                    taking this medicine. Your doctor will perform a pregnancy test
                                    prior to starting Talzenna. </p>
                                <ul>
                                    <li>
                                        <p>You should not use Talzenna if you are pregnant. </p>
                                    </li>
                                    <li>
                                        <p>You should not become pregnant while taking Talzenna.
                                        </p>
                                    </li>
                                    <li>
                                        <p>Discuss contraception with your doctor if there is any
                                            possibility that you or your partner may become
                                            pregnant. </p>
                                    </li>
                                </ul>
                                <p>
                                    <b>Male and female contraception</b>
                                </p>
                                <p><b>Women </b>who are able to become pregnant should use effective
                                    birth control (contraception) during treatment with Talzenna and
                                    for at least 7 months after the last dose of Talzenna. Since the
                                    use of hormonal contraception is not recommended if you have
                                    breast cancer, you should use two non-hormonal contraception
                                    methods.</p>
                                <p>Talk to your healthcare provider about birth control methods that
                                    may be right for you. </p>
                                <p><b>Men </b>with female partners who are pregnant or able to
                                    become pregnant should use effective birth control
                                    (contraception), even after a vasectomy, during treatment with
                                    Talzenna and for at least 4 months after the last dose.</p>
                                <p>
                                    <b>Breast-feeding </b>
                                </p>
                                <p>You should not breast-feed while taking Talzenna and for at least
                                    1 month after the last dose. It is not known if Talzenna passes
                                    into breast milk. </p>
                                <p>
                                    <b>Fertility </b>
                                </p>
                                <p>Talazoparib may reduce fertility in men. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Driving and using machines"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029903"/>
                                <display value="Driving and using machines"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Talzenna may have a minor influence on the ability to drive and
                                    use machines. If you feel dizzy, weak, or tired (these are very
                                    common side effects of Talzenna), you should not drive or use
                                    machines. </p>
                            </div>
                        </text>
                    </section>
                </section>
                <section>
                    <title value="3. How to take Talzenna"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029905"/>
                            <display value="3. How to {take} {use} X"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Always take this medicine exactly as your doctor or pharmacist has
                                told you. Check with your doctor or pharmacist if you are not sure. </p>
                            <p>
                                <b>How much to take </b>
                            </p>
                            <p>The recommended dose is one 1-mg capsule taken by mouth once daily. </p>
                            <p>If you get certain side effects while you are taking Talzenna (see
                                section 4), your doctor may lower your dose or stop treatment,
                                either temporarily or permanently. The dose may be lowered to 0.75
                                mg (taken as three 0.25-mg capsules) once daily, or 0.5 mg (two
                                0.25-mg capsules) once daily, or 0.25 mg (one 0.25-mg capsule) once
                                daily. </p>
                            <p>Swallow the capsule whole with a glass of water. Do not chew or crush
                                the capsules. You can take Talzenna with food or between meals. Do
                                not open the capsules. Contact with the capsule content should be
                                avoided. </p>
                        </div>
                    </text>
                    <section>
                        <title value="If you take more Talzenna than you should"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029907"/>
                                <display value="If you {take} {use} more X than you should"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>If you have taken more Talzenna than your normal dose, contact
                                    your doctor or nearest hospital right away. Urgent treatment may
                                    be necessary. </p>
                                <p>Take the carton and this leaflet so that the doctor knows what
                                    you have been taking. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="If you forget to take Talzenna"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029908"/>
                                <display value="If you forget to {take} {use} X"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>If you miss a dose or vomit, take your next dose as scheduled. Do
                                    not take a double dose to make up for the forgotten or vomited
                                    capsules. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="If you stop taking Talzenna"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029909"/>
                                <display value="If you stop {taking} {using} X"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Do not stop taking Talzenna unless your doctor tells you to.</p>
                                <p>If you have any further questions on the use of this medicine,
                                    ask your doctor or pharmacist or nurse. </p>
                            </div>
                        </text>
                    </section>
                </section>
                <section>
                    <title value="4. Possible side effects"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029910"/>
                            <display value="4. Possible side effects"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Like all medicines, this medicine can cause side effects, although
                                not everybody gets them.</p>
                            <p>
                                <b>Tell your doctor straight away if you notice any of the following
                                    symptoms which could be a sign of serious blood disorder:</b>
                            </p>
                            <p><b>Very common</b> (may affect more than 1 in 10 people)</p>
                            <ul>
                                <li>Being short of breath, feeling very tired, having pale skin, or fast heartbeat – these may be signs
                                    of a low red blood cell count (anaemia).</li>
                                <li>Infection, developing chills or shivering, or fever or feeling hot – these may be signs of a low
                                    white blood cell count (neutropenia).</li>
                                <li>Bruising or bleeding for longer than usual if you hurt yourself – these may be signs of a low
                                    blood platelet count (thrombocytopenia).</li>
                            </ul>
                            <p><b>Talk to your doctor if you get any other side effects. These can include:</b></p>
                            <p><b>Very common</b> (may affect more than 1 in 10 people)</p>
                            <ul>
                                <li>Low counts of white blood cells, red blood cells, and blood platelets</li>
                                <li>Decreased appetite</li>
                                <li>Feeling dizzy</li>
                                <li>Headache</li>
                                <li>Feeling sick (nausea)</li>
                                <li>Being sick (vomiting)</li>
                                <li>Diarrhoea</li>
                                <li>Pain in the abdomen</li>
                                <li>Hair loss</li>
                            </ul>
                            <p><b>Common</b> (may affect up to 1 in 10 people)</p>
                            <ul>
                                <li>Alteration in taste (dysgeusia)</li>
                                <li>Indigestion</li>
                                <li>Mouth inflammation</li>
                            </ul>
                        </div>
                    </text>
                    <section>
                        <title value="Reporting of side effects"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029912"/>
                                <display value="Reporting of side effects"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>If you get any side effects, talk to your doctor or pharmacist or
                                    nurse. This includes any possible side effects not listed in
                                    this leaflet. You can also report side effects directly via the
                                    national reporting system listed in Appendix V. By reporting
                                    side effects you can help provide more information on the safety
                                    of this medicine.</p>
                            </div>
                        </text>
                    </section>
                </section>
                <section>
                    <title value="5. How to store Talzenna"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029913"/>
                            <display value="5. How to store X"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml">
                            <p>Keep this medicine out of the sight and reach of children. </p>
                            <p>Do not use this medicine after the expiry date which is stated on the
                                carton and the bottle or blister after EXP. The expiry date refers
                                to the last day of that month. </p>
                            <p>This medicine does not require any special storage conditions.</p>
                            <p> Do not use this medicine if the pack is damaged or shows signs of
                                tampering. </p>
                            <p>Do not throw away any medicines via wastewater or household waste.
                                Ask your pharmacist how to throw away medicines you no longer use.
                                These measures will help protect the environment. </p>
                        </div>
                    </text>
                </section>
                <section>
                    <title value="6. Contents of the pack and other information"/>
                    <code>
                        <coding>
                            <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                            <code value="200000029914"/>
                            <display value="6. Contents of the pack and other information"/>
                        </coding>
                    </code>
                    <text>
                        <status value="additional"/>
                        <div xmlns="http://www.w3.org/1999/xhtml"> </div>
                    </text>
                    <section>
                        <title value="What Talzenna contains"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029915"/>
                                <display value="What X contains"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <ul>
                                    <li>
                                        <p>The active substance is talazoparib. Talzenna hard
                                            capsules come in different strengths. </p>
                                    </li>
                                    <li>
                                        <p>Talzenna 0.25 mg hard capsules: each capsule contains
                                            talazoparib tosylate equivalent to </p>
                                        <p>0.25 mg talazoparib. </p>
                                    </li>
                                    <li>
                                        <p>Talzenna 1 mg hard capsules: each capsule contains
                                            talazoparib tosylate equivalent to 1 mg talazoparib.</p>
                                    </li>
                                </ul>
                                <p> The other ingredients are: </p>
                                <ul>
                                    <li>
                                        <p>Capsule content: silicified microcrystalline cellulose
                                            (sMCC) (microcrystalline cellulose and silicone
                                            dioxide). </p>
                                    </li>
                                    <li>
                                        <p>0.25 mg capsule shell: hypromellose (HPMC), yellow iron
                                            oxide (E172), and titanium dioxide (E171) </p>
                                    </li>
                                    <li>
                                        <p>1 mg capsule shell: hypromellose (HPMC), yellow iron
                                            oxide (E172), titanium dioxide (E171), and red iron
                                            oxide (E172) </p>
                                    </li>
                                </ul>
                                <p>Printing ink: shellac (E904), propylene glycol (E1520), ammonium
                                    hydroxide (E527), black iron oxide (E172), and potassium
                                    hydroxide (E525). </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="What Talzenna looks like and contents of the pack"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029916"/>
                                <display value="What X looks like and contents of the pack"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Talzenna 0.25 mg is supplied as opaque, approximately 14.30 mm x
                                    5.32 mm hard capsule with an ivory cap (printed with “Pfizer” in
                                    black) and a white body (printed with “TLZ 0.25” in black). </p>
                                <p>Talzenna 1 mg is supplied as opaque, approximately 14.30 mm x
                                    5.32 mm hard capsule with a light red cap (printed with “Pfizer”
                                    in black) and a white body (printed with “TLZ 1” in black). </p>
                                <p>Talzenna 0.25 mg is available in perforated unit dose blister
                                    packs of 30, or 60, or 90 hard capsules and in plastic bottles
                                    of 30 hard capsules. </p>
                                <p>Talzenna 1 mg is available in perforated unit dose blister packs
                                    of 30 hard capsules and in plastic bottles of 30 hard capsules. </p>
                                <p>Not all pack sizes may be marketed. </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Marketing Authorisation Holder and Manufacturer"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029917"/>
                                <display value="Marketing Authorisation Holder and Manufacturer"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Pfizer Europe MA EEIG</p>
                                <p>Boulevard de la Plaine 17 </p>
                                <p>1050 Bruxelles</p>
                                <p>Belgium </p>
                                <p>
                                    <b>Manufacturer </b>
                                </p>
                                <p>Excella GmbH &amp; Co. KG </p>
                                <p>Nürnberger Strasse 12 </p>
                                <p>90537 Feucht</p>
                                <p>Germany </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title
                            value="For any information about this medicine, please contact the local representative of the
                            Marketing Authorisation Holder:"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029918"/>
                                <display
                                    value="This medicine is authorised in the Member States of the European Economic Area {and in the United Kingdom (Northern Ireland)} under the following names:"
                                />
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <table>
                                        <tbody>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>België/Belgique/Belgien Luxembourg/Luxemburg
                                                  </b>
                                                  </p>
                                                  <p>Pfizer NV/SA</p>
                                                  <p>Tél/Tel: +32 (0)2 554 62 11 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Lietuva </b>
                                                  </p>
                                                  <p>Pfizer Luxembourg SARL filialas Lietuvoje </p>
                                                  <p>Tel: + 370 52 51 4000 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>България </b>
                                                  </p>
                                                  <p>Пфайзер Люксембург САРЛ, Клон България </p>
                                                  <p>Тел.: +359 2 970 4333 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Magyarország </b>
                                                  </p>
                                                  <p>Pfizer Kft.</p>
                                                  <p> Tel.: +36-1-488-37-00 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Česká republika </b>
                                                  </p>
                                                  <p>Pfizer, spol. s r.o.</p>
                                                  <p> Tel: +420 283 004 111 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Malta </b>
                                                  </p>
                                                  <p>Vivian Corporation Ltd </p>
                                                  <p>Tel: +356 21344610 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Danmark </b>
                                                  </p>
                                                  <p>Pfizer ApS</p>
                                                  <p> Tlf: +45 44 20 11 00 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Nederland </b>
                                                  </p>
                                                  <p>Pfizer BV</p>
                                                  <p>Tel: +31 (0)10 406 43 01 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Deutschland </b>
                                                  </p>
                                                  <p>PFIZER PHARMA GmbH </p>
                                                  <p>Tel: +49 (0)30 550055-51000 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Norge </b>
                                                  </p>
                                                  <p>Pfizer AS</p>
                                                  <p>Tlf: +47 67 52 61 00 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Eesti </b>
                                                  </p>
                                                  <p>Pfizer Luxembourg SARL Eesti filiaal </p>
                                                  <p>Tel: +372 666 7500 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Österreich </b>
                                                  </p>
                                                  <p>Pfizer Corporation Austria Ges.m.b.H. </p>
                                                  <p>Tel: +43 (0)1 521 15-0 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Ελλάδα </b>
                                                  </p>
                                                  <p>Pfizer Ελλάς A.E.</p>
                                                  <p>Τηλ: +30 210 6785 800 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Polska </b>
                                                  </p>
                                                  <p>Pfizer Polska Sp. z o.o. </p>
                                                  <p>Tel.:+48 22 335 61 00 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>España </b>
                                                  </p>
                                                  <p>Pfizer, S.L.</p>
                                                  <p>Tel: +34 91 490 99 00 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Portugal </b>
                                                  </p>
                                                  <p>Laboratórios Pfizer, Lda. </p>
                                                  <p>Tel: +351 21 423 5500 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>France </b>
                                                  </p>
                                                  <p>Pfizer</p>
                                                  <p>Tél: +33 (0)1 58 07 34 40 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>România </b>
                                                  </p>
                                                  <p>Pfizer Romania S.R.L. </p>
                                                  <p>Tel: +40 (0) 21 207 28 00 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Hrvatska </b>
                                                  </p>
                                                  <p>Pfizer Croatia d.o.o. </p>
                                                  <p>Tel: +385 1 3908 777 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Slovenija </b>
                                                  </p>
                                                  <p>Pfizer Luxembourg SARL</p>
                                                  <p> Pfizer, podružnica za svetovanje s področja
                                                  farmacevtske dejavnosti, Ljubljana</p>
                                                  <p> Tel: + 386 (0)1 52 11 400 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Ireland </b>
                                                  </p>
                                                  <p>Pfizer Healthcare Ireland </p>
                                                  <p>Tel: 1800 633 363 (toll free) +44 (0)1304
                                                  616161 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Slovenská republika </b>
                                                  </p>
                                                  <p>Pfizer Luxembourg SARL, organizačná zložka </p>
                                                  <p>Tel: + 421 2 3355 5500 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Ísland </b>
                                                  </p>
                                                  <p>Icepharma hf.</p>
                                                  <p>Sími: +354 540 8000 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Suomi/Finland </b>
                                                  </p>
                                                  <p>Pfizer Oy</p>
                                                  <p>Puh/Tel: +358 (0)9 43 00 40 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Italia </b>
                                                  </p>
                                                  <p>Pfizer S.r.l.</p>
                                                  <p>Tel: +39 06 33 18 21 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>Sverige </b>
                                                  </p>
                                                  <p>Pfizer AB</p>
                                                  <p>Tel: +46 (0)8 550 520 00 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Kύπρος </b>
                                                  </p>
                                                  <p>Pfizer Ελλάς Α.Ε. (Cyprus Branch) </p>
                                                  <p>Τηλ: +357 22 817690 </p>
                                                </td>
                                                <td>
                                                  <p>
                                                  <b>United Kingdom (Northern Ireland) </b>
                                                  </p>
                                                  <p>Pfizer Limited</p>
                                                  <p>Tel: +44 (0) 1304 616161 </p>
                                                </td>
                                            </tr>
                                            <tr>
                                                <td>
                                                  <p>
                                                  <b>Latvija </b>
                                                  </p>
                                                  <p>Pfizer Luxembourg SARL filiāle Latvijā </p>
                                                  <p>Tel: + 371 670 35 775 </p>
                                                </td>
                                            </tr>
                                        </tbody>
                                </table>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="This leaflet was last revised in MM/YYYY."/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029919"/>
                                <display
                                    value="This leaflet was last revised in {{MM/YYYY}}{{month YYYY}}."
                                />
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>
                                    <b>This leaflet was last revised in MM/YYYY.</b>
                                </p>
                            </div>
                        </text>
                    </section>
                    <section>
                        <title value="Other sources of information"/>
                        <code>
                            <coding>
                                <system value="https://spor.ema.europa.eu/v1/200000029659"/>
                                <code value="200000029920"/>
                                <display value="Other sources of information"/>
                            </coding>
                        </code>
                        <text>
                            <status value="additional"/>
                            <div xmlns="http://www.w3.org/1999/xhtml">
                                <p>Detailed information on this medicine is available on the
                                    European Medicines Agency web site: <xref
                                        href="http://www.ema.europa.eu">http://www.ema.europa.eu</xref>.</p>
                            </div>
                        </text>
                    </section>
                </section>
            </Composition>
        </resource>
    </entry>
</Bundle>
